Osiris Therapeutics (OSIR) Osiris expects to have data in hand (final data collection date for primary outcome measure) by the end of this year for the Phase III evaluation of Prochymal (remestemcel-L), which is an adult human stem cells treatment…
Tag: biopharmas
Synta Pharma: Poised For A Breakout With 4 Near Term Catalysts
Synta Pharmaceuticals Corp. (NASDAQ: SNTA)is a biopharmaceutical company focusing on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug…
Tuesday’s Small Cap Biopharma Catalyst Trade List
Trading biophama stocks before a catalyst event, if done correctly, can be a very profitable proposition. Some traders and investors who enjoy bringing more risk into play often times will hold through the actual catalyst event. While this does bring…
